Name: Latest research reports of Aurobindo Pharma Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Aurobindo Pharma Ltd.
Rating: 5
Author: BOB Capital Markets Ltd.

Aurobindo Pharma Ltd.

NSE: AUROPHARMA | BSE: 524804 | ISIN: INE406A01037 | Industry: Pharmaceuticals
| Mid-range Performer

1090.0000 -7.00 (-0.64%)

NSE Sep 26, 2025 15:31 PM

28.29% Fall from 52W High

Volume: 2.4M

Aurobindo Pharma Ltd.

02 Apr 2020

1090.00

-0.64%

Aurobindo Pharma (BUY): Sandoz deal called off; upgrade to BUY

Buy: Aurobindo Pharma Ltd.

Recommendation Target

BOB Capital Markets Ltd.

Aurobindo Pharma (ARBP) announced that the deal to buy Sandoz's US generic oral solids and dermatology business has been mutually called off.

Aurobindo Pharma Ltd. has lost -27.88% in the last 1 Year